Premium
Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States
Author(s) -
Kim Seoyoung C.,
Sarpatwari Ameet,
Landon Joan E.,
Desai Rishi J.
Publication year - 2020
Publication title -
arthritis and rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.106
H-Index - 314
eISSN - 2326-5205
pISSN - 2326-5191
DOI - 10.1002/art.41201
Subject(s) - biosimilar , medicine , infliximab , citation , family medicine , library science , tumor necrosis factor alpha , computer science